Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +36.67% and -53.66%, respectively, for the quarter ended March 2026. Do…
0,471$
-0,19%
Echtzeit-Aktienkurs BIORESTORAT.THERAP.DL-,01
Bid:
Ask:
Nachrichten zur BIORESTORAT.THERAP.DL-,01 Aktie
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +13.51% and -90.20%, respectively, for the quarter ended December 2025. Do…
BioRestorative Therapies closes $5 million public offering By Investing.com
BioRestorative Therapies closes $5 million public offering…
BioRestorative Announces Closing of $5.0 Million Public Offering
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a…
BioRestorative Announces Pricing of $5.0 Million Public Offering
MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a…
Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 0.00% and -97.00%, respectively, for the quarter ended September 2025. Do…
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this…
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
…
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -75% and 91.67%, respectively, for the quarter ended March 2025. Do…
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript
…
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
…
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do…
BioRestorative Therapies reports Q1 results
…
BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript
…
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc.
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Degenerative Disc Disease - Pipeline Insight, 2024" clinical trials has…